Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis

European Respiratory Journal

Volumn 48, Issue 6, 2016, Pages 1612-1621

  Esther, Charles R ^a,b   Turkovic, Lidija ^c   Rosenow, Tim ^c   Muhlebach, Marianne S ^a,b   Boucher, Richard C ^b   Ranganathan, Sarath ^d   Stick, Stephen M ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMINO ACID; AMOXICILLIN PLUS CLAVULANIC ACID; DORNASE ALFA; GLUTATHIONE; HYPOXANTHINE; PHENYLALANINE; SODIUM CHLORIDE; TYROSINE; XANTHINE; BIOLOGICAL MARKER;

AMINO ACID METABOLISM; ARTICLE; BODY MASS; BRONCHIECTASIS; CELL ENERGY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID ANALYSIS; LUNG DISEASE; LUNG LAVAGE; MALE; MASS SPECTROMETRY; METABOLOMICS; MORPHOMETRY; NEUTROPHIL; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCORING SYSTEM; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; AUSTRALIA; CHEMISTRY; COMPLICATION; INFANT; INFLAMMATION; LIPID METABOLISM; LUNG; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL;

ADENOSINE; AUSTRALIA; BIOMARKERS; BRONCHIECTASIS; BRONCHOALVEOLAR LAVAGE FLUID; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFLAMMATION; LINEAR MODELS; LIPID METABOLISM; LUNG; LUNG DISEASES; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; NEUTROPHILS; OXIDATIVE STRESS; PROGNOSIS;

EID: 85006105563     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00524-2016     Document Type: Article

References (34)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006; 173: 475-482.
2. Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67: 509-516.
3. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155: 623-628.
4. Gangell C, Gard S, Douglas T, et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011; 53: 425-432.
5. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
6. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180: 146-152.
7. Alton EW, Davies JC, Geddes DM. Biomarkers for cystic fibrosis: Are we progressing? Am J Respir Crit Care Med 2007; 175: 750-751.
8. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 822-828.
9. Esther CR Jr, Alexis NE, Clas ML, et al. Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 2008; 31: 949-956.
10. Wolak JE, Esther CR Jr, O'Connell TM. Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers 2009; 14: 55-60.
11. Esther CR Jr, Coakley RD, Henderson AG, et al. Metabolomic evaluation of neutrophilic airway inflammation in cystic fibrosis. Chest 2015; 148: 507-515.
12. Yang J, Eiserich JP, Cross CE, et al. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med 2012; 53: 160-171.
13. Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005; 172: 1246-1252.
14. Rosenow T, Oudraad MC, Murray CP, et al. PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med 2015; 191: 1158-1165.
15. Evans AM, DeHaven CD, Barrett T, et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-6667.
16. Esther CR Jr, Jasin HM, Collins LB, et al. A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Commun Mass Spectrom 2008; 22: 701-705.
17. Esther CR Jr, Lazaar AL, Bordonali E, et al. Elevated airway purines in COPD. Chest 2011; 140: 954-960.
18. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: A comprehensive review. Chest 2010; 138: 682-692.
19. Grasemann H, Shehnaz D, Enomoto M, et al. L-ornithine derived polyamines in cystic fibrosis airways. Plos One 2012; 7: E46618.
20. Kamatani N, Carson DA. Dependence of adenine production upon polyamine synthesis in cultured human lymphoblasts. Biochim Biophys Acta 1981; 675: 344-350.
21. Meng X, Tancharoen S, Kawahara KI, et al. 1, 5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. Int J Immunopathol Pharmacol 2010; 23: 105-119.
22. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2012; 367: 2322-2333.
23. Koeppen M, Di Virgilio F, Clambey ET, et al. Purinergic regulation of airway inflammation. Subcell Biochem 2011; 55: 159-193.
24. Boda D. Role of hyperuricaemia in critically ill patients especially newborns. Acta Paediatr Hung 1984; 25: 23-32.
25. Quinlan GJ, Lamb NJ, Tilley R, et al. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am J Respir Crit Care Med 1997; 155: 479-484.
26. Dauletbaev N, Viel K, Buhl R, et al. Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J Cyst Fibros 2004; 3: 119-124.
27. Kettle AJ, Turner R, Gangell CL, et al. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J 2014; 44: 122-129.
28. Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol 2007; 34: Suppl.5, S8-S12.
29. Pascual E, Sivera F, Yasothan U, et al. Febuxostat. Nat Rev Drug Discov 2009; 8: 191-192.
30. Fahmi AN, Shehatou GS, Shebl AM, et al. Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 269-278.
31. Malinovschi A, Ludviksdottir D, Tufvesson E, et al. Application of nitric oxide measurements in clinical conditions beyond asthma. Eur Clin Respir J 2015; 2: 28517.
32. Patel K, Davis SD, Johnson R, et al. Exhaled breath condensate purines correlate with lung function in infants and preschoolers. Pediatr Pulmonol 2013; 48: 182-187.
33. Esther CR Jr, Boysen G, Olsen BM, et al. Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2009; 296: L987-L993.
34. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011; 23: 319-324.